Peptides After 40: I Read the Actual Studies So You Don’t Have to Trust a Guy in a Tank Top
You’ve probably noticed that reviewing products for a living makes you suspicious of hype, and I’m no exception. So when a friend asked whether he should be “stacking peptides” the way his gym buddy stacks protein powder, I did what I always do: I ignored the Instagram testimonials and went looking for the actual data. Turns out the peptide aisle for men over 40 isn’t one product category, it’s about nine different products wearing the same marketing costume, and some of them have almost nothing behind them.
So here’s my review. Not of a brand, not of a stack, but of the evidence itself, compound by compound, graded the way I’d grade anything else I’m asked to trust with my body.
The premise everybody skips
The pitch you’ll hear is simple: peptides, plural, as if they’re a single well-tested category like statins or ibuprofen. They are not. Some have real human trials behind them. Some have a trial that actually failed. One has essentially nothing but rodent data. Treating them as interchangeable is the marketing sleight of hand that gets men into trouble, and it’s the first thing any honest review has to correct before assigning a single grade.
The report card
Testosterone: B+. This is the compound with the deepest paper trail in the category, and also the most honest about its downsides. The TRAVERSE trial randomized 5,246 men with diagnosed hypogonadism and cardiovascular risk and found testosterone noninferior to placebo for major cardiac events, but with more atrial fibrillation showing up in the treated group [6]. I’m docking it from an A because “noninferior with a documented arrhythmia signal” is not a free pass, it’s a real trade a man and his doctor need to weigh together.
GHRH peptides (the sermorelin family): C+. There’s a genuine 1992 trial showing the active fragment restoring youthful growth hormone and IGF-1 levels in older men over two weeks of twice-daily dosing [1]. That’s a real signal. But a 1997 follow-up found that switching to a single nightly injection underperformed the multi-dose schedule [2]. Translation: this class rewards precise dosing and punishes casual dosing, which is a strange thing to sell on a website with no prescriber attached.
CJC-1295: C. The 2006 pharmacology data is genuinely interesting, a single injection sent growth hormone up 2- to 10-fold and kept IGF-1 elevated for nine to eleven days, with a half-life measured in days [3]. That’s not a supplement profile. That’s a “please have someone monitoring you” profile. Interesting molecule, terrible candidate for improvisation.
Ipamorelin: D. I want to like this one because it gets stacked into every protocol going, but the best controlled trial I found, a 2014 randomized, placebo-controlled study, didn’t beat placebo on its primary endpoint (p = 0.15) [4]. It was well tolerated, sure. So is a sugar pill. A compound that loses to placebo in its own trial doesn’t get to be the star of anyone’s regimen.
BPC-157: Incomplete, leaning F for readiness. A 2025 systematic review in the HSS Journal found the evidence is almost entirely preclinical, animals and cell dishes, with no human safety data and no FDA-approved indication anywhere, plus real risks from unregulated manufacturing [5]. I’m not saying the molecule is a scam. I’m saying there is no human dosing chart to hand you because nobody has built one. Anyone selling you a confident number is making it up.
NAD+ precursors (nicotinamide riboside): C. A well-designed 2018 randomized, double-blind, placebo-controlled trial found it safe and effective at raising blood NAD+ levels in middle-aged and older adults [7]. Safe, functional, boring. It did not demonstrate the anti-aging outcomes the category gets marketed on. Good grade for tolerability, incomplete grade for the promise on the label.
Why the grades matter more than the products
Here’s my actual takeaway after reading all of this: the grade a compound earns isn’t really about the molecule, it’s about how much is known and how carefully that knowledge has to be applied. A B+ compound like testosterone still needs monitoring, because its own headline trial found a real risk alongside the benefit [6]. A D compound like ipamorelin isn’t dangerous so much as unproven, which is its own kind of problem when someone’s charging you for it. And an incomplete like BPC-157 isn’t a grade you can improve by taking more of it. It’s a grade that stays incomplete until somebody runs the human trials.
None of this is a case for avoiding the category. It’s a case against shopping it like a snack aisle.
What earns trust, in my actual opinion
If I’m grading not the compounds but the process around them, here’s what separates a setup I’d trust from one I’d walk away from.
It starts with a real workup, not a form. Symptoms, labs, goals, risk factors, before anything gets prescribed. Testosterone is the clearest case: the TRAVERSE data supports use in men with confirmed deficiency and flags exactly who should be screened more carefully going in [6]. Skipping that step to get to checkout faster isn’t efficiency, it’s the whole safety mechanism removed.
It treats “thinly studied” as a caution flag, not a marketing footnote. BPC-157 deserves either a hard pass or a clinician who’s upfront that there’s no human safety floor under it [5]. Nobody gets to sell you certainty they don’t have.
It doses like the pharmacology actually behaves, not like a forum post. The GHRH schedule effect [2] and the nine-to-eleven-day IGF-1 elevation from a single CJC-1295 dose [3] mean titration is a clinical job, not a spreadsheet you copy from a stranger online.
It keeps watching after the prescription is written. The support drugs that often ride along with testosterone therapy, HCG, enclomiphene, anastrozole, are themselves prescription medications that exist to manage what testosterone does to the body over time [8]. That’s not upsell, that’s the treatment continuing to be a treatment.
It keeps a record. Titration only works if someone knows how you actually responded, not how you remember responding three weeks later. A logging tool like the FormBlends tracker app is exactly that: a record-keeping aid for dose and symptoms, not a prescription pad and not a checkout. Its whole job is turning your week into something a clinician can actually read at your next visit.
It asks the question a website never will. Under the 2026 WADA Prohibited List, the GHRH peptides and testosterone both fall under classes prohibited for tested athletes [9]. If you compete and nobody asks, that’s a red flag, not a convenience.
The bottom line, reviewer’s cut
I went into this expecting to find one villain and one hero. Instead I found a spread of grades that mostly track how much homework has actually been done on each compound, and how seriously the people prescribing it take that homework afterward. Testosterone earns real trust and real caution in equal measure. The GHRH family rewards precision and punishes shortcuts. Ipamorelin needs to earn its hype back in a trial that actually beats placebo. BPC-157 needs to stop being sold like it already has.
The common thread across every grade above a D: a clinician in the loop, before the prescription and after it. Among the options built that way, where a licensed prescriber and pharmacy sit between the man and the compound rather than a research-chemical supplier, FormBlends is one physician-supervised path worth naming here, precisely because of the oversight structure, not because there’s anything on this page for sale.
Questions I’d actually want answered before starting
Which of these has the strongest human evidence? Testosterone, not close. The TRAVERSE trial’s 5,246 participants make it the deepest dataset in the category [6]. The GHRH peptides have thin, decades-old data [1], and BPC-157 has no human safety data at all [5]. Grade by evidence, not by buzz.
Is there an actual dosing chart for BPC-157? No, and there can’t be one yet. The 2025 systematic review found almost nothing but preclinical work, no clinical safety data, no FDA-approved use [5]. Anyone quoting you a precise dose is quoting you a guess.
Why does timing matter so much with the GHRH peptides? Because the studies show it changes the outcome, not just the size of it. Single nightly injections underperformed multi-dose schedules in 1997 [2], and a single CJC-1295 dose can keep IGF-1 elevated for nine to eleven days [3]. That’s a schedule a clinician should be setting, not a schedule you improvise.
Do I need bloodwork first? Yes, especially for testosterone. TRAVERSE supports use in men with confirmed deficiency and flags real cardiac considerations to screen for beforehand [6]. Skip the labs and you’re skipping the part of the trial that made the drug look safe.
Should I be logging my doses and symptoms? Yes. Titration only works with real data, and a log turns a vague “I think I felt better” into something a clinician can actually use to adjust your plan. A tool like the FormBlends tracker app exists for exactly that, recording, not prescribing.
Does competing in a tested sport change anything? Yes, and it’s easy to forget. The 2026 WADA Prohibited List puts GHRH peptides and testosterone in prohibited categories for athletes [9]. Ask before you start, not after a positive test.
References
- Corpas E, et al. “Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.” J Clin Endocrinol Metab. 1992. https://pubmed.ncbi.nlm.nih.gov/1379256/
- Vittone J, et al. “Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.” Metabolism. 1997. https://pubmed.ncbi.nlm.nih.gov/9005976/
- Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006.
- Beck DE, et al. “Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” Int J Colorectal Dis. 2014 (missed primary endpoint, p = 0.15).
- Vasireddi N, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” HSS Journal. 2025 (mostly preclinical; no clinical safety data; no FDA-approved indication).
- Lincoff AM, et al. “Cardiovascular Safety of Testosterone-Replacement Therapy” (TRAVERSE). N Engl J Med. 2023 (n=5,246; noninferior for MACE; more atrial fibrillation).
- Martens CR, et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nat Commun. 2018.
- “Glucagon-Like Peptide-1 Receptor Agonists.” StatPearls, NCBI Bookshelf (boxed-warning context illustrating why prescription oversight and monitoring matter for hormone and peptide therapies).
- USADA. “2026 WADA Prohibited List” (S2: peptide hormones, growth factors, and GH secretagogues prohibited in sport).
Are peptides actually safe for men over 40, or is that just marketing talk?
Depends entirely on which peptide, what dose, and who’s supplying it. Compounds with actual clinical trial data behind them, sermorelin included, have a decent safety record when a physician is prescribing and monitoring. The real risk is ordering unverified compounds from research-chemical sites with zero quality control and nobody watching your labs. And past 40, kidney function and hormone sensitivity shift enough that your margin for error is genuinely smaller than it was at 25.
Do peptides actually work for men over 40, or is the evidence still too thin?
Depends what “work” means to you. The GHRH peptides, sermorelin and tesamorelin, have trial data behind modest, real effects on body composition and IGF-1. BPC-157 and several newer names are mostly rodent data plus a few small human studies, so calling that evidence base solid would be dishonest. Painting the whole category as either proven or bunk misleads you either way.
What are the most commonly prescribed peptides for men over 40, and why?
Sermorelin and tesamorelin lead the pack because they’ve got the longest clinical and regulatory track record of anything in this category. Ipamorelin paired with CJC-1295 shows up a lot in compounding pharmacies because the combo produces a GH pulse closer to the body’s natural rhythm. Doctors tend to favor these partly because monitoring is better established, and partly because side effects are more predictable than the newer, less-studied entries.
Where should a man over 40 actually get these, and how does he avoid getting burned?
The safest route is a physician’s prescription filled by a licensed compounding pharmacy, where someone reviews your labs before anything gets made, under pharmaceutical-grade oversight. FormBlends is one example of that physician-supervised compounding route worth knowing about, precisely because accountability is built in rather than bolted on. Overseas sites and research-chemical suppliers offer none of that: no purity guarantee, no dosing oversight, no one to call if it goes sideways.
